Our lab has an active research program developing biomarkers for neurodegenerative diseases. We support activities of the Brown Center for Alzheimer’s Disease Research and other studies including clinical trials, by providing biofluid biomarker analysis. A long-term research effort for the lab is the CAVU Program – an ambitious undertaking to develop a blood-based biomarker panel sensitive to the broad spectrum of neurodegenerative diseases.
Resilience refers to the maintenance of health despite the presence of otherwise determinant biological or genetic risk factors. We investigate the underlying cellular pathways that confer neurodegenerative disease risk and resilience by examining patient-derived cells from resilient and affected individuals using multiomic approaches together with functional assays.
We are interested in the complex processes that occur during the early development of neurodegenerative disease, with particular focus on the damaging actions of maladaptive immune activation. Experimental therapeutic approaches include reprogramming immune cell metabolism to extend the health of these important brain cells.
